Knisely A, Ahmed J, Stephen B, Piha-Paul SA, et al. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 2023 Oct 21. doi: 10.1002/cncr.35063.
PMID: 37864520